BR9403202A - Method of antibody production or cell-mediated immunity to human immunodeficiency virus, method of protection against infection by human immunodeficiency virus, vaccine and recombinant adenovirus - Google Patents

Method of antibody production or cell-mediated immunity to human immunodeficiency virus, method of protection against infection by human immunodeficiency virus, vaccine and recombinant adenovirus

Info

Publication number
BR9403202A
BR9403202A BR9403202A BR9403202A BR9403202A BR 9403202 A BR9403202 A BR 9403202A BR 9403202 A BR9403202 A BR 9403202A BR 9403202 A BR9403202 A BR 9403202A BR 9403202 A BR9403202 A BR 9403202A
Authority
BR
Brazil
Prior art keywords
immunodeficiency virus
human immunodeficiency
mediated immunity
cell
vaccine
Prior art date
Application number
BR9403202A
Other languages
Portuguese (pt)
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chandra
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9403202A publication Critical patent/BR9403202A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)

Abstract

This invention provides a method of producing antibodies or cell mediated immunity to an infectious organism in a warm blooded mammal which comprises administering to said warm blooded mammal intranasally, intramuscularly, or subcutaneously, live recombinant adenoviruses in which the virion structural protein is unchanged from that in the native adenovirus from which the recombinant adenovirus is produced, and which contain the gene coding for the antigen corresponding to said antibodies or inducing said cell mediated immunity.
BR9403202A 1993-08-11 1994-08-08 Method of antibody production or cell-mediated immunity to human immunodeficiency virus, method of protection against infection by human immunodeficiency virus, vaccine and recombinant adenovirus BR9403202A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10523293A 1993-08-11 1993-08-11
US27628994A 1994-07-20 1994-07-20

Publications (1)

Publication Number Publication Date
BR9403202A true BR9403202A (en) 1995-04-11

Family

ID=26802374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9403202A BR9403202A (en) 1993-08-11 1994-08-08 Method of antibody production or cell-mediated immunity to human immunodeficiency virus, method of protection against infection by human immunodeficiency virus, vaccine and recombinant adenovirus

Country Status (17)

Country Link
EP (1) EP0638316B1 (en)
JP (1) JPH07145079A (en)
KR (1) KR100347220B1 (en)
AT (1) ATE241385T1 (en)
AU (2) AU6889194A (en)
BR (1) BR9403202A (en)
CA (1) CA2130202A1 (en)
DE (1) DE69432730T2 (en)
DK (1) DK0638316T3 (en)
ES (1) ES2196018T3 (en)
FI (1) FI113621B (en)
HK (1) HK1009934A1 (en)
HU (1) HUT69793A (en)
IL (1) IL110560A (en)
NZ (1) NZ264190A (en)
PT (1) PT638316E (en)
SG (1) SG43029A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP1860192A1 (en) * 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
BRPI0504782A (en) 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz recombinant adenoviruses, recombinant adenovirus construction process, toxoplasmosis vaccine composition, and method of immunization against infections caused by the parasite t. gondii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
CA2093427C (en) * 1990-10-17 2008-01-15 Marvin S. Reitz, Jr. Molecular clones of hiv-1 and uses thereof
EP0563323A4 (en) * 1990-12-19 1996-02-28 Epitope Inc Hiv reverse transcriptase vaccine
ES2201055T3 (en) * 1992-08-07 2004-03-16 Wyeth RECOMBINANT ADENOVIRUS VACCINES.

Also Published As

Publication number Publication date
KR100347220B1 (en) 2003-02-26
NZ264190A (en) 1997-06-24
IL110560A0 (en) 1994-11-11
KR950005326A (en) 1995-03-20
HK1009934A1 (en) 1999-06-11
EP0638316B1 (en) 2003-05-28
FI943626A0 (en) 1994-08-04
HUT69793A (en) 1995-09-28
EP0638316A1 (en) 1995-02-15
PT638316E (en) 2003-10-31
DK0638316T3 (en) 2003-09-22
CA2130202A1 (en) 1995-02-12
JPH07145079A (en) 1995-06-06
FI113621B (en) 2004-05-31
DE69432730T2 (en) 2004-03-25
AU4850697A (en) 1998-03-26
HU9402309D0 (en) 1994-10-28
SG43029A1 (en) 1997-10-17
AU6889194A (en) 1995-02-23
IL110560A (en) 1998-10-30
ATE241385T1 (en) 2003-06-15
DE69432730D1 (en) 2003-07-03
FI943626A (en) 1995-02-12
ES2196018T3 (en) 2003-12-16

Similar Documents

Publication Publication Date Title
DE3588254D1 (en) Gag antigen and its use for the detection of LAV infection, as well as in immunogenic compositions
PT586076E (en) RECOMBINANT ADENOVIRUS VACCINES
DK0584348T3 (en) Genetic vaccine against immunodeficiency viruses
DE69531297D1 (en) RECOMBINANT PAPILLOMAVIRUS L1
DK0592546T3 (en) Immunodeficiency virus recombinant poxvirus vaccine
DE68927348D1 (en) ARTIFICIAL VACCINE AGAINST AIDS VIRUS
BR9403202A (en) Method of antibody production or cell-mediated immunity to human immunodeficiency virus, method of protection against infection by human immunodeficiency virus, vaccine and recombinant adenovirus
DK0909323T3 (en) Helicobacter pylori bacterioferritin
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
AU5573196A (en) A pluripotent vaccine against enveloped viruses
PT91316A (en) PROCESS FOR THE PREPARATION OF RECOMBINANT VECTORS AND HBSAG RECOMBINANT HIBRID PARTICLES HAVING THE MORPHOLOGICAL CHARACTERISTICS OF HBSAG ANTIGENIC CONTAINING AN IMMUNOGENIC SEQUENCE THAT INDUCES HIV-DIRECTING NEUTRALIZING ANTIBODIES OR SUSCEPTIVELY OF RECOGNITION BY SUCH ANTIBODIES
CA2286399A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
ATE247485T1 (en) PEPTIDES FOR USE IN VACCINATION AND INDUCTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS

Legal Events

Date Code Title Description
FA Application withdrawn